Type 1 Diabetes Genetic Risk Score classifies diabetes subtypes in Indians: Impact of HLA diversity on the lower discriminative ability - Sankareswaran, Alagu; Kunte, Pooja; Fraser, Diane P; Shaik, Mobeen; Weedon, Michael N; Oram, Richard A; Yajnik, Chittaranjan S; Chandak, Giriraj R (medRxiv, 2024)
Objectives Genetic Risk scores (GRS) classify diabetes types, type 1 (T1D) and type 2 (T2D) in Europeans but the power is limited in other ancestries. We explored the performance of T1DGRS and potential reasons for inferior discrimination ability in diabetes-type classification in Indians.Research Design and Methods In a well-characterized Indian cohort comprising 645 clinically diagnosed T1D, 1153 T2D and 327 controls, we estimated the discriminative ability of T1DGRS (comprising 67 SNPs from Europeans) using receiver operating characteristics-area under the curve (ROC-AUC). We also compared the islet autoantibody status (AA), frequency and effect size of various HLA alleles/haplotypes between Indians and Europeans.Results The T1DGRS was discriminative of T1D from T2D and controls but the ability is lower in Indians than Europeans (AUC=0.83 vs 0.92 respectively, p<0.0001). The T1DGRS was higher in AA-positive patients compared to AA-negative patients [13.01 (12.79-13.23) vs 12.09 (11.64-12.56)], p<0.0001) and showed greater discrimination in the AA-positive T1D (ROC-AUC 0.85). While association of common HLA-DQA1~HLA-DQB1 haplotypes with T1D is replicated, important differences in the risk allele frequency, nature/direction and magnitude of association between Indians and Europeans were noted.Conclusions A T1DGRS derived from Europeans is discriminative of T1D in Indians, highlighting similarity in heritability of T1D. Differences in allele frequency, effect size and directionality, especially in the HLA region are important contributors to inferior discrimination performance of T1DGRS in Indians. Further studies of diverse populations may improve its performance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research is funded by Diabetes UK, London, and the Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India, New Delhi. India.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:King Edward Memorial Hospital and Research Centre, Pune, Maharashtra. India Institutional Ethics Committee KEMHRC ID NO. 1737 KEMHRC ID NO. PHD19I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors